Skip to content Skip to footer
Subscribe Now
EXCLUSIVE

Exclusive: A Stimulating Dialogue with Edmund Ben Ami, Co-Founder & CEO of NeuraLight 

Shots:  Given the high variability and subjectivity of traditional clinical scales, there is an urgent need for objective biomarkers to assess CNS disease progression more reliably    NeuraLight is at the forefront of precision neurology, developing objective and sensitive biomarkers that bring greater accuracy and consistency to CNS research    In this exclusive conversation, Edmund…
October 14, 2025

Read more

VIEWPOINTS

Breaking New Ground in Oncology: Leonard Mazur from Citius Pharmaceuticals in Conversation with PharmaShots 

Shots:   Citius Pharmaceuticals celebrates its first-ever FDA approval with Lymphir, a novel therapy for relapsed or refractory cutaneous T-cell lymphoma     In an exclusive conversation, Leonard Mazur, Co-Founder and CEO at Citius Pharmaceuticals, shares insights on Lymphir’s launch strategy and its potential impact on the oncology landscape    Leonard also highlights Mino-Lok, Citius’ innovative…
October 6, 2025

Read more

EVENTS

Post Conference Highlights: Peptides & Complex Generics Symposium 2025

Day 1 Breakdown The #PCG2025 Symposium commenced on an inspiring note, setting the stage for two days of insightful discussions, collaborations, and knowledge exchange. Opening Session Dr. Ratnesh Jain, Founder & Director, Mumbai Cluster, delivered the inaugural address, sharing his vision of bringing together pharma professionals, R&D experts, CXOs, and academicians to accelerate advancements in…
September 29, 2025

Read more

Mehul Desai from Enable Injections in a Riveting Conversation with PharmaShots
VIEWPOINTS

Wearable Drug Delivery System: Mehul Desai from Enable Injections in a Riveting Conversation with PharmaShots 

Shots:  Enable Injections recently shared survey findings indicating that many oncology assets with strong commercial potential are often prematurely abandoned or deprioritized due to challenges in formulating small volumes (<3 mL) for subcutaneous delivery.  To address this need, Enable Injections developed enFuse, an innovative, hands-free, wearable drug delivery platform with a discreet, hidden needle that…
September 15, 2025

Read more

INSIGHTS+

Know Your Investor: Cormorant Asset Management (September’25 Edition) 

Shots:  Welcome to the September edition of Know Your Investor, featuring leading investors fuelling healthcare & life sciences  This edition spotlights Cormorant Asset Management, an investment firm focused on biotechnology and healthcare companies  In 2024, Cormorant completed 31 investments ~$3.88B, spanning PIPEs, private financings, IPO, and venture rounds. For the full report, contact us at…
September 4, 2025

Read more

EVENTS

HLTH USA 2025 | Oct 19-22 | Las Vegas, NV 

EVERYONE has a heroic story to tell, their own legend to fulfill and HLTH is forging ahead into new realms of possibilities, gathering 12,000+ influential leaders, executives and visionaries who are passionately creating the next generation of healthcare. At HLTH you can foster meaningful connections, gain insights on cutting-edge trends, enhance your professional journey, or…
August 12, 2025

Read more

INSIGHTS+

Know Your Investor: Venrock Healthcare Capital Partners (August’25 Edition)   

Shots:     Welcome to the August edition of Know Your Investor, featuring leading venture capital firms fuelling innovation in healthcare and life sciences  This edition spotlights Venrock Healthcare Capital Partners, a venture capital fund focused on investments in both publicly and privately held healthcare companies  In 2024, Venrock Healthcare Capital Partners invested approximately $4.56B across six…
August 7, 2025

Read more

INSIGHTS+

Know Your Investor: Invus (July’25 Edition)

Shots:      Welcome to the 2025 edition of Know Your Investor, highlighting leading venture capital firms shaping the future of healthcare innovation  This edition highlights Invus, an investment firm focused on supporting life sciences companies committed to advancing breakthroughs that enhance public health  In 2024, Invus invested around $4.15B across six funding rounds, expanding its portfolio…
July 16, 2025

Read more

Load more